TP53 mutations and outcome in osteosarcoma: a prospective, multicenter study.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Journal of Clinical Oncology

• Publication date

  2005-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2005.04.074PMID 15735124
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Alterations of thep53, Rb andMDM2 genes in osteosarcoms

  2005cited by this paper
• Osteosarcoma of the limb. Amputation or limb salvage in patients treated by neoadjuvant chemotherapy.

  2002cited by this paper
• Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols.

  2002cited by this paper
• Primary Osteosarcoma in Adults Older Than 40 Years

  2002cited by this paper
• Surgical outcomes in osteosarcoma.

  2002cited by this paper
• Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: an analysis of 300 patients treated at the Rizzoli Institute.

  2001cited by this paper
• Comparison of two methods of reconstruction for primary malignant tumors at the knee: A sequential cohort study

  2001cited by this paper
• Relative frequency and morphology of cancers in carriers of germline TP53 mutations

  2001cited by this paper
• Assessing TP53 status in human tumours to evaluate clinical outcome

  2001cited by this paper
• Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer.

  2001cited by this paper
• Tissue-specific expression of SV40 in tumors associated with the Li–Fraumeni syndrome

  2001cited by this paper
• Comparison of p53 mutations in patients with localized osteosarcoma and metastatic osteosarcoma

  2001cited by this paper
• MDR1 gene expression and outcome in osteosarcoma: a prospective, multicenter study.

  2000cited by this paper
• Analysis of the p16INK4, p14ARF, p15, TP53, and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma.

  2000cited by this paper
• Co-amplification and overexpression of CDK4, SAS and MDM2 occurs frequently in human parosteal osteosarcomas

  1999cited by this paper
• Disruption of p53 in human cancer cells alters the responses to therapeutic agents.

  1999cited by this paper
• Alteration of pRb/p16/cdk4 regulation in human osteosarcoma

  1999cited by this paper
• CDK4 gene amplification in osteosarcoma: Reciprocal relationship with INK4A gene alterations and mapping of 12q13 amplicons

  1999cited by this paper
• Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy

  1999cited by this paper
• p53 Alteration in regional lymph node metastases from prostate carcinoma

  1999cited by this paper
• TP53 DNA contact mutations are selectively associated with allelic loss and have a strong clinical impact in head and neck cancer

  1998cited by this paper
• Clinicopathologic implications of MDM2, p53 and K-ras gene alterations in osteosarcomas: MDM2 amplification and p53 mutations found in progressive tumors.

  1998cited by this paper
• Cancer phenotype correlates with constitutional TP53 genotype in families with the Li–Fraumeni syndrome

  1998cited by this paper
• p53 gene mutations in osteosarcomas of low-grade malignancy.

  1998cited by this paper
• Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup.

  1997cited by this paper
• p53 and MDM2 alterations in osteosarcomas

  1997cited by this paper
• The status of p53 in the metastatic progression of colorectal cancer.

  1997cited by this paper
• Identification of p53 genetic suppressor elements which confer resistance to cisplatin

  1997cited by this paper
• Alterations of the p53, Rb and MDM2 genes in osteosarcoma.

  1996cited by this paper
• Tumor size and prognosis in aggressively treated osteosarcoma.

  1996cited by this paper
• Tumor size and prognosis in aggressively treated osteosarcoma.

  1996cited by this paper
• Molecular and immunohistochemical identification of p53 alterations in bone and soft tissue sarcomas.

  1996cited by this paper
• Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients

  1996cited by this paper
• Increased incidence of p53 mutations is associated with hepatic metastasis in colorectal neoplastic progression.

  1995cited by this paper
• TP53 mutations and breast cancer prognosis: Particularly poor survival rates for cases with mutations in the zinc‐binding domains

  1995cited by this paper
• MDM2 gene amplification in bone and soft‐tissue tumors: Association with tumor progression in differentiated adipose‐tissue tumors

  1995cited by this paper
• p53 mutations in matched primary and metastatic human tumors

  1995cited by this paper
• Anaplastic Wilms' tumour, a subtype displaying poor prognosis, harbours p53 gene mutations

  1994cited by this paper
• Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness.

  1994cited by this paper
• Tumor spectrum analysis in p53-mutant mice.

  1994cited by this paper
• p53 status and the efficacy of cancer therapy in vivo.

  1994cited by this paper
• Proportional hazards tests and diagnostics based on weighted residuals

  1994cited by this paper
• Parosteal osteosarcoma. A clinicopathological study.

  1994cited by this paper
• Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.

  1994cited by this paper
• Mutation spectrum of the retinoblastoma gene in osteosarcomas.

  1994cited by this paper
• p53 expression and its relationship to DNA alterations in bone and soft tissue sarcomas.

  1993cited by this paper
• p53-dependent apoptosis modulates the cytotoxicity of anticancer agents.

  1993cited by this paper
• Gain of function mutations in p53

  1993cited by this paper
• p53 alterations in non-small cell lung cancers correlate with metastatic involvement of hilar and mediastinal lymph nodes.

  1993cited by this paper
• Mutation spectrum of the p53 gene in bone and soft tissue sarcomas.

  1992cited by this paper
• Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience.

  1992cited by this paper
• The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation.

  1992cited by this paper
• Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours

  1992cited by this paper
• Amplification of a gene encoding a p53-associated protein in human sarcomas

  1992cited by this paper
• Wild-type p53 is a cell cycle checkpoint determinant following irradiation.

  1992cited by this paper
• Maintenance of p53 alterations throughout breast cancer progression.

  1991cited by this paper
• p53 alterations in all stages of breast cancer

  1991cited by this paper
• p53 mutations in ovarian cancer: a late event?

  1991cited by this paper
• Parosteal osteosarcoma. Treatment by wide resection and prosthetic replacement.

  1990cited by this paper
• Many mountains climbed, many yet to conquer.

  1990cited by this paper
• Different tumor-derived p53 mutants exhibit distinct biological activities.

  1990cited by this paper
• Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms.

  1990cited by this paper
• High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene

  1989cited by this paper
• Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults.

  1987cited by this paper
• Osteogenic sarcoma of bones and soft tissues in older persons. A clinicopathologic analysis of 117 patients older than 60 years

  1986cited by this paper
• Parosteal osteosarcoma.

  1984cited by this paper
• The Cincinnati incision: a comprehensive approach for surgical procedures of the foot and ankle in childhood.

  1984cited by this paper
• Juxtacortical (parosteal) osteogenic sarcoma: histological grading and prognosis.

  1977cited by this paper
• Regression Models and Life-Tables

  1972cited by this paper

• Malignant Transformation of Musculoskeletal Lesions with Imaging–Pathology Correlation—Part 1: Bone Lesions

  2025cites this paper
• Osteosarcoma: A Comprehensive Morphological and Molecular Review with Prognostic Implications

  2025cites this paper
• Viral pathogens in bone- and bone-marrow derived malignancies: Friends or foes?

  2025cites this paper
• Genetic profiling of osteosarcoma in an adolescent using a next‑generation sequencing panel and Sanger sequencing: A case report and review of the literature

  2025cites this paper
• Repurposing riluzole as an anti-osteosarcoma agent

  2025cites this paper
• Practical Review of Clinical Research Methodology and Statistics for the Orthopaedic Surgeon.

  2025cites this paper
• Li–Fraumeni‐associated osteosarcomas: The French experience

  2024cites this paper
• Role of proteoglycan synthesis genes in osteosarcoma stem cells.

  2024cites this paper
• The fusion gene LRP1–SNRNP25 drives invasion and migration by activating the pJNK/37LRP/MMP2 signaling pathway in osteosarcoma

  2024cites this paper
• Loss of Function of the Retinoblastoma Gene Affects Gap Junctional Intercellular Communication and Cell Fate in Osteoblasts

  2024cites this paper
• Favorable treatment response to high‐grade sarcoma in neurofibromatosis 1

  2023cites this paper
• Blockade of IL-10 Signaling Ensures Mifamurtide Efficacy in Metastatic Osteosarcoma

  2023cites this paper
• Metformin alleviates adriamycin resistance of osteosarcoma by declining YY1 to inhibit MDR1 transcriptional activity

  2023cites this paper
• Using the canine microbiome to bridge translation of cancer immunotherapy from pre-clinical murine models to human clinical trials

  2022cites this paper
• DEPDC1 as a crucial factor in the progression of human osteosarcoma

  2022cites this paper
• Genomic and proteomic profiling of osteosarcoma

  2022cites this paper
• Regulated cell death and drug resistance in malignant bone tumors

  2022cites this paper
• Connexin43 and development of primary bone tumors

  2022cites this paper
• Canine models of human cancer: Bridging the gap to improve precision medicine.

  2022cites this paper
• Long noncoding RNA HCP5 promotes osteosarcoma cell proliferation, invasion, and migration via the miR‐29b‐3p‐LOXL2 axis

  2022cites this paper
• Depletion of R270C Mutant p53 in Osteosarcoma Attenuates Cell Growth but Does Not Prevent Invasion and Metastasis In Vivo

  2022cites this paper
• Translational cell biology of highly malignant osteosarcoma

  2021cites this paper
• Ubiquitin-specific proteases as therapeutic targets in paediatric primary bone tumours?

  2021cites this paper
• Noncanonical roles of p53 in cancer stemness and their implications in sarcomas.

  2021cites this paper
• Allelic Expression Imbalance Analysis Identified YAP1 Amplification in p53- Dependent Osteosarcoma

  2021cites this paper
• Mechanisms of Resistance to Conventional Therapies for Osteosarcoma

  2021cites this paper
• Alpha Ketoglutarate Exerts In Vitro Anti-Osteosarcoma Effects through Inhibition of Cell Proliferation, Induction of Apoptosis via the JNK and Caspase 9-Dependent Mechanism, and Suppression of TGF-β and VEGF Production and Metastatic Potential of Cells

  2020cites this paper
• Identification of tumorigenicity-associated genes in osteosarcoma cell lines based on bioinformatic analysis and experimental validation

  2020cites this paper
• DEPDC1/ EEF1A1 complex promotes the progression of human osteosarcoma via downregulation of FOXO3a

  2020cites this paper
• Osteosarcoma

  2020cites this paper
• Osteosarcoma: A comprehensive review of management and treatment strategies.

  2020cites this paper
• Comparative analysis of genome-wide DNA methylation identifies patterns that associate with conserved transcriptional programs in osteosarcoma

  2020cites this paper
• Osteoidbildende Knochentumoren

  2020cites this paper
• Genomics and the Immune Landscape of Osteosarcoma.

  2020cites this paper
• Osteosarcoma of the jaws: An overview of the pathophysiological mechanisms.

  2020cites this paper
• Canine osteosarcoma genome sequencing identifies recurrent mutations in DMD and the histone methyltransferase gene SETD2

  2019cites this paper
• New challenges in integrated diagnosis by imaging and osteo-immunology in bone lesions

  2019cites this paper
• The regulatory role of aberrant methylation of microRNA-34a promoter CpGs in osteosarcoma

  2019cites this paper
• Targeting mutant TP53 as a potential therapeutic strategy for the treatment of osteosarcoma

  2019cites this paper
• TP53 in bone and soft tissue sarcomas.

  2019cites this paper
• Clinical Genomic Sequencing of Pediatric and Adult Osteosarcoma Reveals Distinct Molecular Subsets with Potentially Targetable Alterations

  2019cites this paper
• An Insight into the Roles of MicroRNAs and Exosomes in Sarcoma

  2019cites this paper
• Lkb1 deletion in periosteal mesenchymal progenitors induces osteogenic tumors through mTORC1 activation

  2019cites this paper
• Immunohistochemical detection of p53, PTEN, Rb, and p16 in canine osteosarcoma using tissue microarray

  2018cites this paper
• Fluorescent In Situ Hybridization for TP53 in the Diagnosis of Pediatric Osteogenic Sarcoma

  2018cites this paper
• Genetic determinants of childhood and adult height associated with osteosarcoma risk

  2018cites this paper
• Transforming Growth Factor-β Signaling Plays a Pivotal Role in the Interplay Between Osteosarcoma Cells and Their Microenvironment

  2018cites this paper
• Chondroblastic osteosarcoma of maxil­la, a patient with Li- Fraumeni syndrome

  2018cites this paper
• Extracellular Vesicle RNA Sequencing Reveals Dramatic Transcriptomic Alterations Between Metastatic and Primary Osteosarcoma in a Liquid Biopsy Approach

  2018cites this paper
• JNK pathway mediates curcumin-induced apoptosis and autophagy in osteosarcoma MG63 cells

  2017cites this paper
• A Dog in the Cancer Fight: Comparative Oncology in Osteosarcoma

  2017cites this paper
• Distinctive Head and Neck Bone and Soft Tissue Neoplasms.

  2017cites this paper
• Novel siRNA formulation to effectively knockdown mutant p53 in osteosarcoma

  2017cites this paper
• The Requirement of p53 in Oral MSC differentiation Which Leads to Kaposi’s Sarcoma

  2016cites this paper
• TP53 Mutations and Survival in Osteosarcoma Patients: A Meta-Analysis of Published Data

  2016cites this paper
• The progress of molecular diagnostics of osteosarcoma.

  2016cites this paper
• The requirement of p 53 in oral MSC differentiation which leads to Kaposi ’ s Sarcoma Master ’ s Thesis

  2016cites this paper
• Prognostic Value of Vascular Invasion in Pediatric Osteosarcomas

  2016cites this paper
• The Journal of Clinical Investigation

  2016cites this paper
• Chapter 28 – Cytogenetic and molecular genetic alterations in bone tumors

  2015cites this paper
• The Oncolytic Adenovirus VCN-01 as Therapeutic Approach Against Pediatric Osteosarcoma

  2015cites this paper
• Research progress on the multidrug resistance mechanisms of osteosarcoma chemotherapy and reversal

  2015cites this paper
• Targeted Chemotherapy in Bone and Soft-Tissue Sarcoma.

  2015cites this paper
• Unscrambling the genomic chaos of osteosarcoma reveals extensive transcript fusion, recurrent rearrangements and frequent novel TP53 aberrations

  2015cites this paper
• Utilization of a canine cancer cell line (FACC) panel in comparative and translational studies of gene expression and drug sensitivity

  2015influential citation
• Gene and proteomic profiling of osteosarcoma

  2015cites this paper
• Chapter 36 – Apoptosis and drug resistance in malignant bone tumors

  2015cites this paper
• Involvement and Targeted Intervention of Deregulated Hedgehog Pathway in Osteosarcoma

  2014influential citation
• Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma.

  2014influential citation
• Proximal Tumor Location and Fluid-fluid Levels on MRI Predict Resistance to Chemotherapy in Stage IIB Osteosarcoma

  2014cites this paper
• Translational biology of osteosarcoma

  2014cites this paper
• Molecular mechanisms of chemoresistance in osteosarcoma (Review)

  2014cites this paper
• Clinicopathologic Characteristics of Brain Tumors are Associated with the Presence and Patterns of TP53 Mutations: Evidence from the IARC TP53 Database

  2014cites this paper
• Epigenetic alterations in osteosarcoma: promising targets

  2014cites this paper
• Development and translational imaging of a TP53 porcine tumorigenesis model.

  2014cites this paper
• Exomic analysis of myxoid liposarcomas, synovial sarcomas, and osteosarcomas

  2014influential citation
• Digital Expression Profiling Identifies RUNX2, CDC5L, MDM2, RECQL4, and CDK4 as Potential Predictive Biomarkers for Neo-Adjuvant Chemotherapy Response in Paediatric Osteosarcoma

  2014cites this paper
• Canine osteosarcoma: a naturally occurring disease to inform pediatric oncology.

  2014cites this paper
• Prognostic value of p53 alterations in human osteosarcoma: a meta analysis.

  2014cites this paper
• Novel p53 splicing site mutation in Li‐Fraumeni‐like syndrome with osteosarcoma

  2013cites this paper
• TP53 Mutations and Chemotherapy Response to Neoadjuvant Metotrexate, Cisplatin and Adryamicin Chemotherapy in Resected Osteosarcoma

  2013cites this paper
• Clinicopathologic significance of histologic grade, pgp, and p53 expression in canine lymphoma.

  2013cites this paper
• Update on targets and novel treatment options for high-grade osteosarcoma and chondrosarcoma.

  2013cites this paper
• MicroRNA paraffin-based studies in osteosarcoma reveal reproducible independent prognostic profiles at 14q32

  2013cites this paper
• Protein Kinase C Epsilon and Genetic Networks in Osteosarcoma Metastasis

  2013cites this paper
• Neoadjuvant and adjuvant chemotherapy with high-dose ifosfamide, doxorubicin, cisplatin and high-dose methotrexate in non-metastatic osteosarcoma of the extremities: a phase II trial in Japan

  2013cites this paper
• Mechanisms of therapy resistance in osteosarcoma: a review

  2013cites this paper
• The identification and analysis of molecular biomarkers in the p53 tumour suppressor pathway that affect cancer progression in humans

  2013cites this paper
• Li–Fraumeni syndrome: a role for surgical pathologists?

  2012cites this paper
• The Retinoblastoma Protein in Osteosarcomagenesis

  2012cites this paper
• Molecular pathology and its diagnostic use in bone tumors.

  2012cites this paper
• Genetically engineered mouse models and human osteosarcoma

  2012cites this paper
• Alternate splicing of the p53 inhibitor HDMX offers a superior prognostic biomarker than p53 mutation in human cancer.

  2012cites this paper
• MicroRNA-34a Inhibits the Proliferation and Metastasis of Osteosarcoma Cells Both In Vitro and In Vivo

  2012cites this paper
• The Molecular Basis of Sarcoma

  2011cites this paper
• Functional characterization of osteosarcoma cell lines provides representative models to study the human disease

  2011cites this paper
• Improving outcomes for patients with musculoskeletal tumours

  2011cites this paper
• Alternative splicing of HDMX predicts p53 inactivation and bad prognosis

  2011influential citation
• Molecular and genetic basis of childhood cancer

  2011cites this paper
• Tumeurs et pseudotumeurs osseuses, oncogenèse et microenvironnement

  2011cites this paper